65 results about "Tail Suspension" patented technology

The invention discloses a Chinese medicinal composition for treating tristimania, which is prepared into certain formulations by taking curcuma longa, St John's wort and ginseng as raw materials, and extracting and separating the raw materials by using 0-75 percent ethanol. An animal toxicity test result shows that 284 times of an adult dosage of the medicinal composition for lavaging a mouse causes no acute toxicity reactions; a pharmacodynamic study shows that the medicinal composition can significantly perform antagonism on acinesia and hypothermia, induced by reserpoid, of a tristimania model mouse, and can increase the number of autonomic activities and the dead time for tail suspension and swimming, induced by the tail suspension and forced swimming, of a desperate animal model. A clinical research result shows that by adopting a Hamilton rating scale for depression (HAMD) to evaluate the depression severity which serves as the primary therapeutic effect index, a treatment group obtains a significant curative effect, the effective rate is 92.3 percent, and compared with a control group, the medicinal composition has significant differences but has no toxic and side effects. The medicinal composition can be prepared into medically acceptable oral preparations, such as tablets, capsules (soft capsules or hard capsules), granules and the like; and the clinical curative effect and the pharmacodynamic study prove that the medicinal composition has the functions of smoothing the liver to alleviate mental depression and relieving mental stresses, and is an effective special medicament for treating the tristimania.

The present invention discloses a medicine made from paeoniflorin for curing depression and the dosage thereof. The present invention has the following main technical characteristics: the effective dosage of the paeoniflorin is 80 to 400mg / day; the optimal dosage is 150 to 300mg / day; the best dosage is 220mg / day. The present invention also discloses the preparation method of the medicine. The experiment proves that the medicine provided by the present invention can obviously reduce tail suspension fixed time and reserpine-induced temperature dropping of tested mice, thus concluding that the medicine provided by the present invention has the efficacy of experimental depression resistance.

The invention discloses a tail suspension mouse cage which comprises at least one mouse cage unit, mouse suspension cavities are limited in the mouse cage units, partition plates are slidably arrangedin the mouse suspension cavities, the mouse suspension cavities are divided into two mouse suspension spaces, the sizes of the two mouse suspension spaces can be adjusted by sliding the partition plates, suspension devices are mounted above the mouse suspension spaces and comprise sliding cross rods, suspension springs, suspension rings and tail tying mechanisms, the sliding cross rods are slidably arranged at the tops of the mouse suspension spaces, the suspension rings are arranged on the sliding cross rods in a sleeving manner, one end of each suspension spring is connected with the corresponding suspension ring, the other end of each suspension spring is connected with the corresponding tail tying mechanism, the tail of an experimental mouse can be suspended by the tail tying mechanism, the tail is firmly fixed, wound is omitted, mouse tail damage and mouse tail dividing injury or mouse tail avascular necrosis can be omitted, and the number of samples and accuracy of experimentalresults are ensured.